Announcement on the Reappointment of the Company's Audit Institution for the Year 2026
Beijing Saiseng Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company") and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, with no false records, misleading statements, or significant omissions.
Special Reminder: The reappointment of the accounting firm complies with the regulations set forth in the "Management Measures for the Selection of Accounting Firms by State-owned Enterprises and Listed Companies" issued by the Ministry of Finance, the State-owned Assets Supervision and Administration Commission of the State Council, and the China Securities Regulatory Commission (CSRC) (Cai Kuai [2023] No. 4).
On March 29, 2026, the Company held the 13th meeting of the 5th Board of Directors, where it reviewed and approved the proposal to reappoint Crowe Horwath (Special General Partnership) as the Company's audit institution for the year 2026. The relevant matters are announced as follows:
I. Basic Information of the Proposed Accounting Firm
(1) Firm Information
- Basic Information
- Name of the accounting firm: Crowe Horwath (Special General Partnership)
- Date of establishment: 1981
- Registered address: 5th Floor, Sait Plaza, No. 22 Jianguomenwai Street, Chaoyang District, Beijing
- Chief Partner: Li Huiqi
- Issuing authority and certificate number: Beijing Municipal Finance Bureau NO 0014469
As of the end of 2025, Crowe Horwath has nearly 6,000 employees, including 244 partners and 1,361 certified public accountants, with over 400 certified public accountants having signed audit reports for securities services.